7:01 AM ET
8-K
Investor Presentation
Minerva Neurosciences Investor Presentation
Minerva Neurosciences hosted a Key Opinion Leader (KOL) event and filed an updated investor presentation regarding roluperidone, its product candidate for schizophrenia. The filing includes a revised transcript of the event to clarify that regulatory counsel's expressions of confidence regarding FDA approval were personal opinions and not assurances of future regulatory decisions.